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The discovery of small molecules targeting the >80
enzymes that add (methyltransferases) or remove
(demethylases) methyl marks from lysine and argi-
nine residues, most notably present in histone tails,
may yield unprecedented chemotherapeutic agents
and facilitate regenerativemedicine. To better enable
chemical exploration of these proteins, we have
developed a highly quantitative microfluidic capillary
electrophoresis assay to enable full mechanistic
studies of these enzymes and the kinetics of their
inhibition. This technology separates small biomole-
cules, i.e., peptides, based on their charge-to-mass
ratio.Methylation, however, does not alter the charge
of peptide substrates. To overcome this limitation,
we have employed a methylation-sensitive endopro-
teinase strategy to separate methylated from unme-
thylated peptides. The assay was validated on a
lysine methyltransferase (G9a) and a lysine demethy-
lase (LSD1) and was employed to investigate the
inhibition of G9a by small molecules.
INTRODUCTION
The epigenetic code is written on DNA in the form of methylation,
and on histone proteins as methylation, acetylation, phosphory-
lation, ubiquitination, sumoylation, and ADP-ribosylation (Gelato
and Fischle, 2008). The four main histone proteins (H2A, H2B,
H3, and H4) form an octomeric unit around which 147 bp of
DNA are wrapped to make a nucleosome, which is the repeating
unit of chromatin. Histone proteins contain flexible N-terminal
tails that protrude from the nucleosome core where the bulk of
these posttranslation modifications are ‘‘written,’’ ‘‘read,’’ and
‘‘erased’’ by a myriad proteins. The most commonly modified
residues are lysine, which can be acetylated or methylated,
and arginine, which can be methylated. The pattern of modifica-
tions influences chromatin architecture, ultimately controlling theChemistry & Biology 17,temporal and spatial access of transcription factors to specific
genes (Kouzarides, 2007).
Since the discovery of the first histone lysine methyltransfer-
ase in 2000 (Rea et al., 2000), >50 protein lysine methyltrans-
ferases (PKMTs) and >10 protein arginine methyltransferases
(PRMTs) have been identified. These enzymes transfer a methyl
group from the cofactor S-adenosylmethionine (SAM) to the
3-amino group of lysine or the guanidine group of arginine,
most likely through an SN2 mechanism where the lone pair of
electrons on nitrogen attack the electrophillic methylsulfonium
group on SAM, producing the byproduct S-adenosylhomocys-
teine (SAH) (Copeland et al., 2009). Lysine residues can be
mono-, di-, or trimethylated, while the guanidine group of argi-
nine can be monomethylated, asymmetrically dimethylated, or
symmetrically dimethylated. In addition, since the first histone
demethylase was discovered in 2004 (Shi et al., 2004), at least
30 enzymes belonging to this family have been identified (Cope-
land et al., 2009), indicating that histonemethylation is a dynamic
process. Among the demethylating enzymes, there are the
flavin-dependent monoamine oxidases like LSD1, and the JmjC
domain demethylases. LSD1-like demethylases convert mono-
or di- but not trimethylated amino groups to imines that are
subsequently nonenzymatically hydrolyzed, while JmjC-domain
demethylases utilize iron and a-ketoglutarate cofactors to
hydroxylate mono-, di, or trimethyl lysines (Trewick et al., 2005)
and even methylated arginines (Chang et al., 2007). In both
cases, the hydroxylated methyl groups spontaneously hydro-
lyze, releasing formaldehyde, the by-product of catalysis that
retains the carbon of the oxidized methyl group. While the
activity of protein methyltransferases and demethylases is syn-
onymous with histone modification, there is increasing evidence
for their role in modification of other nuclear and cytosolic
proteins such as p53 (Huang et al., 2007, 2010), various
transcription factors (Couture et al., 2006), WIZ, histone deace-
tylases, DNA methyltransferases, and even the protein methyl-
transferases themselves (Rathert et al., 2008). Recognition of
methyl-lysine marks has been associated with the ‘‘Royal
Family’’ of proteins including those containing Tudor, Chromo,
Maligant Brain Tumor (MBT), PWWP, and plant Agenet domains,
the plant homeodomain (PHD) family, and the WD40 repeat
protein WRD5. These motifs all have structurally related binding695–704, July 30, 2010 ª2010 Elsevier Ltd All rights reserved 695
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donors that interact with the lysine cation (Adams-Cioaba and
Min, 2009). Many chromatin-acting enzymes, including a vast
number that modify histones, contain these domains that recruit
them to their site of action, and the development of small
molecule antagonists of methyl-lysine recognition is another
area of active interest (Wigle et al., 2010).
The bioorthogonal relationship between protein methyltrans-
ferases and protein demethylases influences how the histone
code is read by methyl-lysine binding proteins and ultimately
has a profound effect on the pattern of gene expression in a
particular cell. Mounting evidence suggests that many diseases
are rooted in epigenetic misregulation, and that therapies target-
ing epigenetic processes may be a revolutionary strategy to
combat illness in the future (Cole, 2008; Keppler and Archer,
2008). It is known that overexpression of any one of a number
of protein methyltransferases or demethylases can lead to a
variety of cancers (Copeland et al., 2009; Spannhoff et al.,
2009a), inflammation (Li et al., 2008), cardiovascular disease
(Chen et al., 2006), and neurological disorders (Tahiliani et al.,
2007). In addition, these enzymes are fundamental to cellular
fate and may be manipulated in cellular reprogramming efforts
(Shi et al., 2008a, 2008b). Therefore, high-quality chemical
probes (Frye, 2010) of protein methyltransferases and demethy-
lases will enhance our understanding of their potential as
therapeutic targets and may ultimately lead to pharmacological
agents for a variety of afflictions.
To facilitate the development of chemical probes for the
enzymes that write and erase histone methyl marks, we have
developed a highly quantitativemicrofluidic capillary electropho-
resis (MCE) assay that distinguishes between methylated and
unmethylated histone peptides and providesmechanistic insight
into the inhibition of these enzymes by small molecules. MCE
operates on the principle that small biomolecules taken from
nanoliter-sized aliquots of reaction samples are separable in a
capillary quartz channel based on their charge-to-mass ratio
when a current is applied. This technique can be performed
in high-throughput fashion and has been adopted as a gold
standard assay in the profiling of small molecule inhibitors of
kinases, proteases, and histone acetyltransferases (HATs) and
deacetylases (HDACs), which modify the isoelectric points of
their peptide substrates.
Methylation, however does not alter the charge-to-mass ratio
of peptide substrates. To overcome this hurdle to assay devel-
opment on this highly quantitative platform, we have employed
a methylation-sensitive protease cleavage strategy to distin-
guish betweenmethylated and unmethylated peptides. The ratio
of substrate-to-product peak sizes is determined, providing very
accurate and reproducible measurements of conversion and
detailed insights into enzyme kinetics. Parameters such as Ki,
Km, and kcat can be measured with confidence and the mecha-
nism of action of putative inhibitors can be probed, enhancing
the efficacy of compound profiling efforts in the early stages of
drug discovery. These advantages distinguish this assay format
over other methods, such as the incorporation of radioactive
methyl groups using 3H-SAM, AlphaScreen (Quinn et al., 2010)
and ELISA-based detection (Kubicek et al., 2007) of methylated
peptide substrates, and enzyme-coupled measurement of SAH
production (Collazo et al., 2005). These techniques either suffer696 Chemistry & Biology 17, 695–704, July 30, 2010 ª2010 Elsevier Lfrom an inability to generate high-quality kinetic data or are
difficult to automate, and, in the case of radioactive assays,
can be hazardous to the operator. We applied this assay to
G9a, a lysine methyltransferase, and LSD1, a lysine demethy-
lase, demonstrating a broad potential for the application of this
assay to enzymes that alter the methylation state of peptide
substrates. Therefore, microfluidic capillary electrophoresis re-
presents a sophisticated methodology capable of establishing
a new standard in both the precision and accuracy with which
small molecule inhibitors of protein methyltransferases and
demethylases are identified and evaluated.
RESULTS
Detection of Methylation-Sensitive Peptide Cleavage
Since methylation does not alter the electrophoretic properties
of peptides, an endoproteinase-coupled strategy was used to
distinguish between unmethylated and methylated histone
peptides in a microfluidic mobility shift assay. Endoproteinase-
LysC (Endo-LysC) cleaves peptide bonds that are on the
C-terminal side of lysine residues and is commonly used in
mass spectrometric analysis of proteins. Recently, Boa et al.
reported that the mass spectrometry profiles of Endo-LysC-di-
gested histone H3 extracted from yeast cells having a set1
methyltransferase knockout differed greatly from extracts of
wild-type cells and hypothesized that the Endo-LysCwas unable
to cleave after methylated lysines (Boa et al., 2003). Therefore,
we surmised that methylation-sensitive endoproteinase cleav-
age could be a novel method to assay histone methylation and
demethylation in the context of an in vitro assay (Figure 1).
To verify that Endo-LysC would selectively cleave peptides
after unmodified lysines, an initial experiment was designed
using two synthetic peptides labeled with fluorescein that are
representative of unmethylated and monomethylated lysine 9
on histone H3 (H3K9me1). Different ratios of the unmethylated
(1) and monomethylated (5) peptides were mixed such that the
total peptide concentration was 1 mM, Endo-LysC was added,
and electrophoretic separation of the reaction products was
performed. It was observed that Endo-LysC was unable to
cleave the peptide containing the monomethylated lysine but
was able to fully cleave >97% of the peptide containing the
unmodified lysine in less than 1 hr, indicated by the appearance
of a second peak (Figure 2A). The amount of methylated peptide
detected corresponded well with the calculated amount of
methylated peptide actually added (Figure 2B).
Design of Substrates for Methyltransferase
and Demethylase Enzymes
Having established that MCE could be used to distinguish
between methylated and unmethylated peptides, the next step
was to demonstrate that this assay could be used to monitor
the activity of enzymes that alter the methylation state of peptide
substrates (Figure 3). In designing substrates, it is important
to consider the position of the fluorescein tracer relative to the
location of Endo-LysC susceptible lysine residues to balance
substrate turnover with the ease of electrophoretic separation
(Figure 3D). The first and most straightforward example of this
strategy is the design of a substrate for G9a (EHMT2). G9a
targets lysine 9 on histone peptide H3 and has been shown totd All rights reserved
Figure 1. Methylation-Sensitive Endopro-
teinase-Linked Microfluidic Capillary
Electrophoresis Assay Concept
Protein lysine methyltransferases (PKMT)
methylate substrate peptides, which prevents
proteolysis of the peptide at the target lysine by
endoproteinase-LysC. Protein lysine demethy-
lases (PKDM) demethylate peptide substrates
and render it susceptible to proteolysis by endo-
proteinase-LysC. The cleaved versus uncleaved
peptides are separable on a Caliper Life Sciences
EZ Reader II, which ‘‘sips’’ nanoliter-sized
samples from reactions in microplate wells into a
capillary channel on a quartz chip. A pressure
driven flow and electric current are used to resolve
the peptides based on their charge-to-mass ratio.
The incorporation of a fluorescein-based tracer
enables the detection of the peptides at the end
of the capillary channel. This assay format is
compatible with 384-well microplates, can be per-
formed in volumes as low as 10–15 ml, and is
a widely used technology in drug discovery.
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site (Rathert et al., 2008). Initial attempts to use peptide 1 (the
8-mer peptide spanning residues 5–14 of the H3 peptide) as
a G9a substrate did not result in methylation-dependent protec-
tion from Endo-LysC digestion (data not shown). To investigate
whether the peptide length and omission of residues 1–4 of the
histone H3 peptide was responsible for the lack of G9a activity,
a longer peptide (2) spanning residues 1–14 of the H3 peptide
was synthesized, with fluorescein on the terminal K14 residue.
To simplify the analysis of cleavage products, lysine 4 was
premethylated during synthesis of the peptide to prevent
Endo-LysC digestion at this position. Using peptide 2 as sub-
strate for lysine 9 methylation, robust protection of peptide
cleavage was observed, corresponding to G9a methyltransfer-
ase activity (Figures 3A and 3B). The velocity of three reactions
with different G9a concentrations was measured by taking
aliquots at various time points with or without a heatkill step to
deactivate the enzyme. The reaction velocities obtained by either
method corresponded well, with slightly higher conversion
observed for reactions without a heatkill step. We concludedChemistry & Biology 17,that heatkill is not necessary when looking at relative G9a
kinetics, for example, the determination of inhibitor IC50 values,
as the presence of 40 pg/ml Endo-LysC rapidly digests both
the peptide and G9a, concluding the reaction. However, as
described in the following sections, when examining absolute
kinetic parameters for G9a, such as Km, kcat, and Ki, we found
that terminating the reaction with a cocktail of Endo-LysC and
a known G9a inhibitor, UNC0224, produced the best results.
To further demonstrate the applicability of this assay concept
across the families of enzymes that alter the methylation state of
histone peptides, we explored the possibility of monitoring the
activity of LSD1 (AOF2), a lysine demethylase. For LSD1, sub-
strate design was more complex than in the case of G9a, and
several factors were taken into consideration. LSD1 is known
to demethylate mono- and dimethyl lysine 4 of histone H3
peptide (H3K4me1/2), and previous reports have shown that
LSD1 activity is commensurate with longer peptides that
span at least 20 residues (Forneris et al., 2005). However, the
H3 peptide spanning residues 1–22 contains multiple lysines
that could be subject to cleavage by Endo-LysC, and it isFigure 2. Separation of HistoneH3Peptides
Representative of Unmethylated and
Monomethylated Lysine 9 on the Caliper
EZ Reader II
Ratios of H3K9me0 (peptide 1) and H3K9me1
(peptide 5) adding up to 1 mM total peptide were
mixed and Endo-LysC was added. After 1 hr, the
products were separated on the Caliper EZ
Reader II.
(A) The direct readout from the EZ Reader II
showing the separation of products ‘‘sipped’’
from the 384-well plate containing titrations of
the H3K9me1 to H3K9me0 peptide.
(B) A correlation plot of the experimentally de-
tected amount of methylated peptide detected
versus the calculated ratio of methylated to unme-
thylated peptides added.
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Figure 3. Substrate Design and Activity
Measured for G9a Methyltransferase and
LSD1 Demethylase Enzymes Using the
MCE Assay Platform
Activity of G9a and LSD1 with heatkill (open
symbols) or direct addition to Endo-LysC (closed
symbols) to terminate the reaction. G9a and
LSD1 were present at three different concentra-
tions as indicated on the plots.
(A) G9a reaction with 500 nM of peptide 2 present.
(B) G9a reaction with 5000 nM of peptide 2
present.
(C) LSD1 reaction with 2000 nM peptide 4.
(D) Pairs of initial and optimized histoneH3 peptide
substrate designs for G9a and LSD1 enzymes.
Endo-LysC susceptible sites are indicated by
triangles and lysine residues targeted by G9a or
LSD1 are underlined. The 5/6-FAM group in each
peptide is attached to the lysine 3-amino group,
indicated by the K(FAM) designation. The de-
tected substrate (solid line) and product (dashed
line) species resulting from Endo-LysC digestion
are indicated beneath the peptide sequences.
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the site of demethylation in order to retain maximum substrate
turnover. To address these considerations in LSD1 substrate
design, two H3 peptides spanning residues 1–22 were evalu-
ated. Both peptides were synthesized with monomethylation at
lysine 4, and one peptide had all other lysines replaced by
alanine except for lysine 22, which contained the fluorescein
group (peptide 3), while the other peptide kept all lysines intact,
and fluorescein was included internally on lysine 9 (peptide 4). In
the case of peptide 4, it was expected that all other lysines would
undergo cleavage, but the fluorescein label on lysine 9 would
prevent proteolysis at that position. Therefore, the success of
the assay using peptide 4 would rely on the separation of
peptides spanning residues 1–14 or 5–14 depending on the
activity of LSD1. Ultimately, peptide 3 having all other lysines
substituted for alanines was not demethylated by LSD1, but
peptide 4 having an internally fluoresceinated lysine 9 led to
the detection of robust and linear LSD1 activity. Again, three
concentrations of LSD1 were reacted with 2 mM peptide 4 and
time points were sampled with or without a heatkill step (Fig-
ure 3C).Weobserved that for smallmolecule screening, a heatkill
step is not necessary.
Measurement of G9a Lysine Methyltransferase Kinetics
After demonstrating that we could detect time-dependent G9a
methylation of peptide 2, the use of the assay was extended to
the measurement of kinetic parameters Km and kcat. Reactions
containing titrations of either SAM or the peptide weremonitored
as a function of time. The conversion of substrate to product was
determined and subjected to a linear regression analysis
(Figures 4A and 4B) to measure the initial velocities of the reac-
tion as a function of the titrant concentration (Figures 4C and 4D).
Between both experiments, the following parameters were
calculated: kcat of 13 ± 3 min
1, Km
SAM of 31.7 mM, and Km
peptide
of 36.2 mM. The affinity for both substrates was similar, as were
the maximal reaction velocities, consistent with this reaction698 Chemistry & Biology 17, 695–704, July 30, 2010 ª2010 Elsevier Lproceeding as a bimolecular SN2 mechanism (Copeland et al.,
2009).
Configuring the G9a Methyltransferase Assay
for Small Molecule Screening
Microfluidic capillary electrophoresis assays on the Caliper
LabChip platform are used in the pharmaceutical industry for
small molecule screening and profiling of protein target classes
such as kinases, phosphodiesterases, HDACs, HATs, and prote-
ases. The reliable and robust performance of this assay platform
is well suited for the screening of chemical libraries and profiling
of hits in the early stages of drug discovery so that potential leads
can be confidently assessed for potency and selectivity. To take
advantage of this assay platform in our ongoing efforts to develop
potent and selective chemical probes of PKMTs (Liu et al., 2009),
the assay was miniaturized and automated for use with small
molecules. Since DMSO is the universal solvent used in small
molecule screening, the DMSO tolerance of the G9a assay was
determined (Figure 5A). Both Endo-LysC andG9a retained nearly
full activity at up to 10%DMSO, making this assay well suited for
both routine screening of small molecules at the standard
concentration of 1% DMSO, and in fragment-based screens
where the compounds are added at higher concentrations,which
requires the presence of elevated DMSO concentrations.
Using low-volume 384-well microplates, the assay volume
was decreased more than 3-fold (50–15 ml), thereby saving
valuable protein and reagents. The workflow was greatly accel-
erated by the use of a multidrop dispenser to add reagents to the
384-well plates. To examine the robustness of this automated
assay, the methylation of peptide 2 in minimum and maximum
control reactions was recorded on two 384-well plates on con-
secutive days, where the minimum signal control is performed
in the absence of SAM. An average Z0 factor (Zhang et al.,
1999) of 0.92 was determined with CV values of less than 2%,
indicating that this assay is suitable for small molecule screening
(Figure 5B).td All rights reserved
Figure 4. Determination of Km and Vmax
with Respect to Peptide 2 or SAM in the
G9a MCE Assay
Peptide 2 or SAM was titrated by the indicated
amounts and time points were taken at fixed inter-
vals so that reaction velocity could be determined
and Michaelis-Menten kinetics were plotted.
(A and C) The peptide titration indicates a Km
peptide
of 36.2 mM and kcat of 15.5 min
1. (B and D) The
SAM titration indicates a Km
SAM of 31.7 mM and
kcat of 11.1 min
1. The standard error of the
mean in three separate reactions is indicated by
error bars in (A) and (B).
Chemistry & Biology
Capillary Electrophoresis for PKMTs and PKDMsOur group has explored the structure-activity relationship of
compounds based upon the quinazoline template of BIX-
01294, a validated cell-permeable inhibitor of G9a and GLP
methyltransferases (Kubicek et al., 2007). A cocrystal structure
of BIX-01294 bound to GLP, which is more than 80% homolo-
gous to G9a in the catalytic domain (Chang et al., 2009), was
used to guide initial efforts. In particular, substitutions at theChemistry & Biology 17, 695–704, July 30, 20107-methoxy position of the quinazoline
were made to explore the possibility of
extending groups into the lysine binding
channel of G9a, and the benzyl group
that did not make any favorable interac-
tions with the protein was removed
(Figure 5E). This led to the discovery ofUNC0224, which is more potent than BIX-01294 and is the first
small molecule inhibitor to be cocrystallized with G9a (Liu
et al., 2009). The high-resolution X-ray structure of UNC0224
bound to G9a confirmed that its 7-dimethylamino propoxy
substituent occupied the lysine binding channel, leading to
greatly enhanced affinity for the enzyme. To gauge the ability
of this assay to support further probe discovery efforts, theFigure 5. Configuring the G9a MCE Assay
for Small Molecule Screening
(A) DMSO sensitivity curves for G9a and
Endo-LysC.
(B) Statistical evaluation of the maximum and
minimum signal control reactions of the assay
over the course of 2 days results in an average Z0
factor of 0.92 and CVs of less than 2%.
(C) Graphical representation of the IC50 values
measured for 83 small molecules over the course
of two independent runs of the assay indicates
excellent correlation between dose response
assays.
(D) A plot of Hill Slope versus the IC50 measured
indicates two major clusters of compounds: (1)
Compounds with Hill Slope of roughly 1 and
potency >5 nM are rank-ordered by the assay,
(2) while compounds with Hill Slope >1 and
IC50 <5 nM have reached the potency detection
limit of the assay. UNC0224 and BIX-01294 are
indicated on the plot. The observation that
IC50 values of as little as 2 nM can be measured
is likely a reflection of the fraction of active G9a
among the 10 nM enzyme added.
(E) Structure guided design of UNC0224 from the
BIX-01294 quinazoline template.
ª2010 Elsevier Ltd All rights reserved 699
Figure 6. Measuring a Ki for the Known Peptide-Competitive G9a Methyltransferase Inhibitor UNC0224
(A) The velocity of the reaction was determined by analyzing six time points spanning 100 min and analyzed by linear regression to determine the Vobs values.
(B) The measured Km
obs and (C) Vmax values plotted as a function of UNC0224 concentration.
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inhibitors was assessed. While the structure-activity profile
generated is beyond the scope of this paper and will be pre-
sented in full detail elsewhere, we report excellent correlation
between the IC50 values obtained in two independent runs of
the assay (Figure 5C). However, as shown in Figure 5D, two
groups of compounds were evident: (1) those having a Hill Slope
of close to 1, with IC50 values spanning a range of 5 nM to 30 mM,
and (2) compounds with Hill Slopes of greater than 1, with IC50
values of less than 5 nM. A steep Hill Slope is indicative that
the assay potency limit has been exceeded, with the theoretical
limit of IC50 detection for tight binding inhibitors to be half the
total enzyme concentration (Copeland, 2000), which in this
case is 10 nM G9a. Strategies for investigating the rank order
of these very potent compounds and their mechanism of action
are outlined below.
Determination of Ki of UNC0224 versus Peptide 2
Approximately 25% of the compounds synthesized in the
UNC0224 series reached the potency limit of the assay. The
cocrystal structure of G9a and UNC0224 (PDB 3K5K), which is
at least 10-fold more potent than BIX-01294, guided further
inhibitor design. While diversity or fragment-based screening
would normally be performed at 500 nM peptide using this
assay, quinazoline analogs were screened at 5 mM of competing
peptide substrate to enhance the ability to resolve more potent
compounds. Nonetheless, the potency limit of the assay was
exceeded by a substantial number of compounds tested;
therefore, competitive Kis were determined for this interaction.
Using UNC0224 as a benchmark, the compound was titrated
using a 1.5-fold dilution scheme from 13.3 to 0.7 nM, and
aliquotswere sampled at various time points by adding a cocktail
of Endo-LysC and a saturating concentration (5 mM) of UNC0224
to stop the reaction immediately. Fitting the initial rates of
reaction observed at each peptide concentration to Michaelis-
Menten kinetics yielded parameters associatedwith the peptide,
Km and Vmax, which were plotted as a function of the UNC0224
concentration (Figure 6). This confirmed that UNC0224 is
competitive with the peptide substrate, as the Km increased
linearly with UNC0224 concentration and the Vmax remained
unchanged. A linear regression of the observed Km at each
UNC0224 concentration was performed, and, using the
relationship Ki = Km/slope, the Ki of UNC0224 was determined
to be 1.6 nM.700 Chemistry & Biology 17, 695–704, July 30, 2010 ª2010 Elsevier LProfiling SAM Competition Using a Rapid
Endpoint-Based Variation of the G9a Assay
To expand the diversity of known G9a inhibitors both focused
and diversity-based chemical libraries should be screened. In
order to differentiate compounds with other possible modes of
inhibition including SAM-competitive or allosteric regulators,
a rapid endpoint method for profiling SAM-competitive inhibitors
was developed. In contrast to the determination of the absolute
Ki through time-dependent analysis of methyltransferase reac-
tions, the goal was to use minimal reagent while generating
kinetic fingerprints of inhibitors that would allow assessment of
the mechanism of inhibition, i.e., competitive with SAM or the
peptide, or noncompetitive with either. Since the peptide is the
most costly reagent in the assay, running fullKis for SAM compe-
tition would be prohibitive as it would require saturating concen-
trations of roughly 50 mM. To reduce the peptide requirement,
Km
app and Vmax
app for SAM were determined at multiple inhibitor
concentrations using only 500 nM peptide. The apparent Km for
SAM at 500 nM peptide was 294 ± 3 nM in the absence of inhib-
itor, about 100-fold less than the absolute Km, and the Vmax
app
measured under these conditions was 7.4 ± 0.1 nM/min, about
60-fold less than the absolute Vmax. To test this method for
comparing inhibition modes, the concentration-dependence of
Km
app and Vmax
app was determined for UNC0224, and Sinefun-
gin, a known SAM-competitive inhibitor of methyltransferases
(Figure 7). Indeed, Sinefungin displayed a typical SAM-compet-
itive profile where Km
app increased with compound concentra-
tion, while Vmax
app remained relatively unchanged, and Ki
app
for Sinefungin was 18 mM. UNC0224 appeared to be noncom-
petitive with SAM, with Km
app remaining constant with increasing
compound concentration, while the Vmax
app decreased asymp-
totically.
DISCUSSION
Epigenetics is an emerging area of drug discovery that may
expand approaches to treat diseases with small molecules.
Currently there are only four FDA-approved drugs that target
the enzymes that regulate the modification state of chromatin,
suberoylanilide hydroxamic acid (SAHA, Vorinostat) and Romi-
depsin (Istodax), which reversibly inhibit histone deacetylases
(HDACs), and 5-aza-20deoxycytidine\50-azacytidine (Decitabine\
Vidaza), which target DNA methyltransferases irreversibly after
incorporation into DNA by polymerase. The discovery of thesetd All rights reserved
Figure 7. A Rapid Endpoint Method for the Assessment of Competition with Respect to SAM in G9a Methyltransferase MCE Assay
To conserve reagent, we determined the influence of inhibitors on SAM-dependent kinetic parameters using less-than-saturating peptide, finding a quick
and effective way to fingerprint hits for an inhibitory mechanism of action.
(A and B) The SAM analog, Sinefungin, exhibited the increased Km
app and constant Vmax
app that are hallmarks of a SAM-competitive inhibitor and yielded a Ki
app
of 18 mM.
(C and D) The peptide-competitive inhibitor UNC0224 does not alter the Km
app, but results in asymptotically decreasing Vmax
app, traits which are indicative of
an inhibitor that is noncompetitive with SAM.
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where the identity of the cellular target was not initially appreci-
ated (Friedman, 1979; Marks, 2007). The eventual link between
the cellular targets of these drugs and their therapeutic utility
has attracted much attention to the small molecule manipulation
of chromatin-regulating proteins, and there are now entire
research programs and private enterprises devoted to the
discovery of small molecules that act upon epigenetic targets
(Karberg, 2009). The link between the misregulation of histone
methylation and a variety of diseases (Spannhoff et al., 2009b)
and the availability of high-resolution X-ray structures for many
of these proteins (Marmorstein and Trievel, 2009) are aligned
to stimulate and enable the discovery of small molecules that
regulate these enzymes. In addition, opportunities to modulate
nonhistone proteins, i.e., p53 is known to be the target of both
G9a (Huang et al., 2010) and LSD1 (Huang et al., 2007), provide
both increased therapeutic potential and a challenge to under-
standing the selectivity and in vivo mechanism of action of
inhibitors. The precedent that lysine acetylation is now rivaling
protein phosphorylation in importance suggests that we are
only beginning to realize the implications of lysine methylation
and its consequences for cellular signaling and metabolism
(Norvell and McMahon, 2010). High-quality chemical probes
will undoubtedly play a major role in expanding knowledge in
this area (Frye, 2010).
Currently, there are several biochemical assays available that
are capable of supporting early stage research for the discoveryChemistry & Biology 17,of potent and selective inhibitors of the enzymes that regulate
protein lysine methylation. However, these methods can be
hazardous to the operator (radioactivity assays), can be hard
to automate (Thioglo assay), or lack the ability to measure
enzyme kinetics and are susceptible to compound interference
(AlphaScreen). Here, a robust and highly quantitative microflui-
dic capillary electrophoresis platform is detailed for the study
of protein lysine methyltransferase and demethylase enzy-
mology and the effect that small inhibitors have on these
enzymes. The assay works by taking advantage of the fact that
Endo-LysC, which cleaves peptide bonds on the C-terminal
side of lysine residues, is inhibited by lysine methylation. Using
a rational approach to the design of peptide substrates, the
viability of this assay format was demonstrated for the study of
G9a lysine methyltransferase and LSD1 lysine demethylase.
The positions of the Endo-LysC susceptible residues and the
fluorescein tracer were optimized for substrate turnover, while
balancing electrophoretic separation on a Caliper Life Sciences
EZ Reader II. The G9a and LSD1 substrates presented here
may also serve as model substrates for extending this assay to
other enzymes that act on the same residues, H3K9 and H3K4
(experiments underway). In addition, the activity of PRMT3, a
protein arginine methyltransferase, was detected using endo-
proteinase-ArgC to differentiate between unmethylated and
methylated arginine (data not shown) and optimization is
ongoing. This technique is advantageous for the investigation
of methylation and demethylation due to its versatility in both695–704, July 30, 2010 ª2010 Elsevier Ltd All rights reserved 701
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As opposed to radioactive assays, bulk reagents can be safely
handled, permitting large-scale diversity screening. The fluores-
cein tracer used to detect both substrate and product is not as
susceptible to compound interference as the signal transduction
cascade of AlphaScreen or the Thioglo chromophore. In addi-
tion, unlike the Thioglo method, the assay performs well as
a miniaturized and automated assay, and it far exceeds the
ability of AlphaScreen to measure kinetics.
The G9a assay was configured for small molecule inhibitor
screening, having a Z0 factor 0.92 and excellent robustness
and reproducibility. The assay is well suited to support screening
and compound profiling activities as demonstrated using
a collection of 83 small molecule analogs of UNC0224 (Liu
et al., 2009) to study the inhibition of G9a (Figure 5). While the
structure-activity relationship of these compounds is beyond
the scope of this paper and will be presented elsewhere, the
assay reproducibly rank ordered the compounds in independent
runs. However, it was also noticed that compounds clustered
into two groups: (1) compounds with Hill slope z1 and IC50 >
5 nM, and (2) ultrapotent peptide-competitive inhibitors,
indicated by a Hill Slope > 1 and IC50 < 5 nM. The original
template, BIX-01924 belongs to cluster 1, while UNC0224 falls
into cluster 2, and this assay permitted the rigorous characteriza-
tion of UNC0224. UNC0224 is competitive with the peptide
substrate, having a Ki of 1.6 nM, consistent with the binding
mode in the cocrystal structure of UNC0224 with G9a
(Liu et al., 2009). Additionally, an abbreviated method was
used to confirm that UNC0224 was noncompetitive with SAM,
while Sinefungin was competitive with SAM, exhibiting a Ki
app
of 18 mM. Taken together, this appears to be a highly effective
method to analyze the effect of small molecules on these enzyme
families.
This methylation-sensitive endoproteinase cleavage assay
performed on an MCE platform is a practical and highly
quantitative method to study the kinetics of protein lysine
methyltransferases and demethylases that take peptides from
an unmethylated state to methylated state or vice versa.
However, it is not applicable to enzymatic reactions that do not
involve an unmethylated state in the substrate or product. It is
envisioned that research groups without access to a Caliper
EZ Reader II will be able to employ a variation of the methyla-
tion-sensitive endoproteinase assay strategy on fluorescence
polarization (FP), fluorescence resonance energy transfer
(FRET), or AlphaScreen platforms.
SIGNIFICANCE
Posttranslational modifications of histone proteins form the
basis of the epigenetic code, which controls the structural
state of chromatin and influences gene expression profiles
from cell to cell. The enzymes responsible for writing,
reading, and erasing these modifications are important
targets for chemical biology and drug discovery due to their
roles in stem cell biology and the etiology of numerous
diseases. In particular, the discovery of small molecules
targeting the >80 enzymes that add (methyltransferases) or
remove (demethylases) methyl marks from lysine and argi-
nine residues present in histone tails may yield novel thera-702 Chemistry & Biology 17, 695–704, July 30, 2010 ª2010 Elsevier Lpeutics. To advance our chemical biology efforts in the
design of modulators of histone methylation, we have
developed an assay for protein methyltransferases and
demethylases that is well suited for the profiling of small
molecules for potency and selectivity among enzyme family
members.
Microfluidic capillary electrophoresis is advantageous
for its ability to monitor the formation of product and disap-
pearance of substrate, delivering highly quantitative results
and enhancing the sensitivity of assays configured for this
platform. However, monitoring lysine methylation presents
a challenge for this technique: methylation does not alter
the isoelectric properties of peptides substantially, and
therefore substrates and products of methylation/demethy-
lation reactions are not separable. In this work, methylation-
sensitive endoproteinase-cleavage is used as a tool to
enable the application of this technology to examine the
kinetics of protein methyltransferases and demethylases.
This technique was used to profile both peptide- and
SAM-competitive inhibitors of G9a methyltransferase in
addition to enabling the measurement of Ki values and
rank-ordering of inhibitor potency. This assay is well suited
to drive both high-throughput screening and chemical
biology efforts toward the development of potent and
selective modulators of protein methylation.
EXPERIMENTAL PROCEDURES
Materials
Endoproteinase-LysC (Endo-LysC) was obtained as a lyophilized powder from
Pierce via Thermo Fisher Scientific (Waltham, MA) and resuspended to
a concentration of 1 ng/ml in 25 mM Tris-HCl (pH 8) then aliquoted and stored
at –80C. Three hundred eighty-four-well V-bottom polypropylenemicroplates
were purchased from Greiner (Monroe, NC), and 384-well low volume shallow
microplates were purchased fromNunc via Thermo Fisher Scientific (Waltham,
MA). S-adenosylmethionine (SAM) was purchased from New England Biolabs
(Ipswich, MA). Sinefungin was purchased from Sigma-Aldrich (St. Louis, MO),
and all other reagents were obtained from Fisher Scientific. Inhibitors of G9a
methyltransferase used in assay development were synthesized in our labora-
tory and will be published with full chemical characterization elsewhere. The
catalytic domain of G9a (residues 913–1193) was purified as previously
described (Wu et al., 2010). LSD1 was purchased from two different sources:
BPS Biosciences (San Diego, CA) and Enzo Life Sciences (Farmingdale, NY).
In all cases, the assay buffer used was 20 mM Tris-HCl, 25 mM NaCl, 0.025%
Tween 20, and 1 mM DTT (pH 8).
Peptides
Several peptides containing a 5-carboxyfluorescein tracer (5-FAM, abbrevi-
ated to FAM below) were used in assay development. All peptides were
synthesized and high-performance liquid chromatography (HPLC) purified
by either the Tufts University Peptide Synthesis Core Facility (Boston, MA) or
Intonation Technologies (West Roxbury, MA) and contained N-terminal amino
and C-terminal amide groups. The inclusion of a monomethylated lysine is
indicated by K(me1). Two peptides, QTARKSTGGK(FAM) (1) and QTARK
(me1)STGGK(FAM) (5) were used in the proof-of-principle experiments to
validate the methylation-sensitive endoproteinase-coupled assay strategy.
The optimized G9a substrate was the histone H3 peptide ARTK(me1)
QTARKSTGGK(FAM) (2). Two peptides representative of histone H3 were
tested for LSD1 activity, ARTK(me1)QTARASTGGAAPRAQLAK(FAM) and (3)
ARTK(me1)QTARK(FAM)STGGKAPRKQLAK (4).
G9a Lysine Methyltransferase Assays
Methylated and unmethylated peptides were separated following endopro-
teinase digestion on a Caliper LabChip EZ Reader II equipped with a 12-sippertd All rights reserved
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using EZ Reader software (Caliper Life Sciences, Hopkinton, MA). The initial
G9a activity assay was performed in a microcentrifuge tube by premixing
G9a and peptide 2, and initiating the reaction with the addition of 50 mM
SAM. Time points (10 ml) were sampled with and without a heatkill step
(5 min exposure to 80C) and added to 40 pg/ml Endo-LysC in a 384-well
V-bottom polypropylenemicroplate. Themeasurement of G9amethyltransfer-
ase kinetics was performed in 50 or 15 ml volumes in 384-well polypropylene
V-bottom or shallow microplates using 25 nM G9a and either 50 mM SAM or
50 mM peptide 2 and initiated by addition of either SAM or peptide 2. Parallel
reactions were set up and allowed to proceed at 25C, and aliquots were
analyzed by stopping the reaction with 10 ml of a cocktail Endo-LysC
(40 pg/ml) and UNC0224 (Liu et al., 2009) (5 mM), which was added to immedi-
ately inhibit all further enzyme activity. Inhibitor-substrate competitions were
set up similarly, and the contribution of DMSO concentration from compound
addition was maintained at 1%. All dose-response assays (IC50s) of putative
G9a inhibitors were set up by preincubating a cocktail of 25 nM G9a and
5 mMpeptide with the inhibitors for 10 min at 25C and initiated by the addition
of 10 mM SAM. The concentration of DMSO was maintained at 1%, and
minimum signal controls were run in the absence of SAM. After incubation
for 1 hr at 25C, 40 pg/ml Endo-LysC was added and allowed to digest the
remaining unmethylated substrate peptide (and the G9a) for at least 30 min
prior to separation on the EZ Reader II. The separation of peptide 2 was
performed under the following optimized conditions: upstream voltage =
500 V, downstream voltage = 1200 V, and pressure = 1.5 psi using a
marker dye consisting of peptide 2 that was completely predigested with
Endo-LysC.
LSD1 Lysine Demethylase Assays
The measurement of LSD1 kinetics was performed in a microcentrifuge tubes
and initiated by adding peptide 4 to LSD1 and allowed to proceed at 25C.
Aliquots (10 ml) were sampled at various time points both with and without
a heatkill step (5 min exposure to 80C) and added to 40 pg/ml Endo-LysC in
a 384-well shallow microplate with proteolysis of the methylated substrate
peptide (and the LSD1) for at least 30 min prior to separation on the EZ Reader
II. The separation of peptide 4 was performed under the following optimized
conditions: upstream voltage = 500 V, downstream voltage = 2000 V,
and pressure = 1.7 psi using a marker dye consisting of peptide 4 that was
predigested with Endo-LysC.
Data Analysis
Enzyme kinetics and parameters such as Km and Ki were determined using
Prism software (GraphPad Software Inc, San Diego, CA) to analyze Michae-
lis-Menten fits of initial enzyme velocities. Automated dose-response runs
were analyzed using ScreenAble software (Screening Solutions LLC, Chapel
Hill, NC) and IC50 values and Hill Slopes were generated using four parameter
fits. The quality and robustness of the assay was determined by analysis of the
Z0 factor (Zhang et al., 1999):
Z0 = 1

3smax + 3smin
jmmax  mminj

;
where smax and smin are standard deviations of the respective maximum and
minimum signal controls, and mmax and mmin are the averages of the respective
maximum and minimum signal controls.
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